(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
27 June 2002 (27.06.2002)

PCT

(10) International Publication Number:
WO 02/49651 A1

(51) International Patent Classification[7]: A61K 31/519, A61P 9/08, 15/10

(21) International Application Number: PCT/EP01/13916

(22) International Filing Date:
28 November 2001 (28 11 2001)

(25) Filing Language: German

(26) Publication Language: German

(30) Priority Data:

100 63 224 6	19 December 2000 (19 12 2000)	DE
100 63 882 1	21 December 2000 (21 12 2000)	DE
100 64 993 9	23 December 2000 (23 12 2000)	DE

(71) Applicant *(for all designated States except US)*: **MERCK PATENT GMBH** [DE/DE], Frankfurter Strasse 250, 64293 Darmstadt (DE)

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **EGGENWEILER, Hans-Michael** [DE/DE], Erbacher Strasse 49, 64287 Darmstadt (DE) **EIERMANN, Volker** [DE/DE], Geranienstrasse 18, 63322 Rodermark (DE)

(74) Common Representative: **MERCK PATENT GMBH**; Frankfurter Strasse 250, 64293 Darmstadt (DE)

(81) Designated states *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

(84) Designated states *(regional)* ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK,

[continued overleaf]

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING PUYRAZOLO[4,3-D]PYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES



(I)

(57) Abstract: Pharmaceutical preparation comprising at least one compound of the formula (I) in which R^1, R^2, R^3, R^4 and X are as defined in Claim 1, and physiologically acceptable salts and/or solvates thereof and a) at least one antithrombotic or b) at least one calcium antagonist or c) at least one prostaglandin or prostaglandin derivative, for the preparation of a medicament for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), corpulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis and for the treatment of female sexual disorders

162162

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette